The Board of Pharmacy has received notice of the following product withdrawal:

Description	Lot # / Exp Date	NDC	UPC
RANITIDINE MDV 25MG/ML MYLN6ML	7051222 6/30/21; 7051221 6/30/21; 7050886 6/30/20; 7050881 6/30/20; 7050859 5/31/20	67457039862	36745739862
RANITIDINE SDV 50MG/2ML MYLN10	7051223 6/30/21; 7050883 5/31/20; 7050882 5/31/20; 7050860 5/31/20	67457039799	36745739799

Mylan is withdrawing the above items/lots due to an FDA request to all manufacturers of Ranitidine products to withdraw from the market all Ranitidine products due to the presence of NDMA in some of these products. This withdrawal is to the retail level. Affected product started shipping August 2018.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.